Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chronic Heart Failure (CHF)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    88 result(s) found for: Chronic Heart Failure (CHF). Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2005-004487-22 Sponsor Protocol Number: BMI 001 / SMR-1389 Start Date*: 2005-11-25
    Sponsor Name:Bio-Medisinsk Innovasjon AS
    Full Title: A Proof of Biological Efficacy Study Assessing the Potential of Piboserod a Specific 5-HT4 Antagonist for the Treatment of Symptomatic Congestive Heart Failure in stable outpatients NYHA class II-I...
    Medical condition: Congestive heart failure
    Disease: Version SOC Term Classification Code Term Level
    4.0 10010684 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002809-48 Sponsor Protocol Number: CRO782 Start Date*: 2013-04-17
    Sponsor Name:Imperial College London and Imperial College Healthcare NHS Trust
    Full Title: Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure and a left ventricular assist device
    Medical condition: Advanced heart failure
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000220-33 Sponsor Protocol Number: CLCZ696BDE03 Start Date*: 2019-02-04
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, double-blind, active-controlled study to assess the effect of sacubitril/valsartan compared with enalapril to improve erectile function in patients with heart failure with reduced eje...
    Medical condition: Patients with heart failure with reduced ejection fraction (HFrEF) and erectile dysfunction (ED)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008502 CHF LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004600-53 Sponsor Protocol Number: RBK03-16-00389 Start Date*: 2018-06-08
    Sponsor Name:WÖRWAG Pharma GmbH & Co. KG
    Full Title: MACH 2 - Magnesium orotate in severe congestive heart failure - Part 2
    Medical condition: Heart failure with reduced ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019284 Heart failure, congestive LLT
    20.1 100000004849 10064081 Heart failure NYHA class III LLT
    20.1 100000004849 10064080 Heart failure NYHA class II LLT
    20.1 100000004849 10064082 Heart failure NYHA class IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002673-38 Sponsor Protocol Number: CRLX030A2211 Start Date*: 2015-11-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, crossover placebo-controlled Phase II study to assess the effect of serelaxin versus placebo on high sensitivity cardiac troponin I (hs-cTnI) release in pat...
    Medical condition: Chronic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001994-27 Sponsor Protocol Number: 2006B180 Start Date*: 2007-09-03
    Sponsor Name:Academisch Medisch Centrum
    Full Title: The effect of beta-adrenergic receptor blockade on sympathetic activity and coagulation in patients with heart failure (BACH-F study)
    Medical condition: Congestive heart failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020352-59 Sponsor Protocol Number: GHF112670 Start Date*: 2010-07-29
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multi-center, placebo-controlled study to evaluate the safety of GSK716155 and its effects on myocardial metabolism, myocardial function, and exercise capacity in patients with NYHA Class II/III ...
    Medical condition: NYHA Class II/III congestive heart failure.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000473-20 Sponsor Protocol Number: CLCZ696B3402 Start Date*: 2016-08-18
    Sponsor Name:Novartis Pharma services AG
    Full Title: A prospective evaluation of natriuretic peptide based referral of CHF patients in primary care
    Medical condition: Chronic heart failure with reduced ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000126-19 Sponsor Protocol Number: SPIHF-204 Start Date*: 2016-08-01
    Sponsor Name:Stealth BioTherapeutics Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment with Elamipretide in Patients Hospitalized with Congestion due to Hear...
    Medical condition: Congestive heart failure
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) NL (Completed) ES (Completed) HU (Completed) GB (Completed) BG (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003968-39 Sponsor Protocol Number: 2015CA02 Start Date*: 2017-09-19
    Sponsor Name:University of Dundee/NHS Tayside
    Full Title: Renal and Cardiovascular Effects of SGLT2 inhibition in combination with loop diuretics in diabetic patients with chronic heart failure.
    Medical condition: Type 2 diabetes and heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    20.0 100000004849 10010684 Congestive heart failure LLT
    20.0 100000004849 10019279 Heart failure LLT
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021263-33 Sponsor Protocol Number: 3001101 Start Date*: 2011-05-24
    Sponsor Name:Sykehuset i Vestfold HF
    Full Title: PERIOPERATIVE LEVOSIMENDAN INFUSION IN PATIENTS WITH HEART FAILURE UNDERGOING NON-CARDIAC SURGERY: A PROSPECTIVE, RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY
    Medical condition: Patients with serious cardiac failure scheduled for non-cardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10006387 Broken hip LLT
    14.1 10007541 - Cardiac disorders 10007559 Cardiac failure congestive PT
    14.1 10007541 - Cardiac disorders 10007554 Cardiac failure PT
    14.1 10007541 - Cardiac disorders 10066498 Cardiac failure chronic aggravated LLT
    14.1 10007541 - Cardiac disorders 10007558 Cardiac failure chronic PT
    14.1 10007541 - Cardiac disorders 10024102 Left cardiac failure LLT
    14.1 10007541 - Cardiac disorders 10007561 Cardiac failure left LLT
    14.1 10007541 - Cardiac disorders 10007555 Cardiac failure (NOS) LLT
    14.1 10007541 - Cardiac disorders 10007564 Cardiac failure, congestive LLT
    14.1 10007541 - Cardiac disorders 10007562 Cardiac failure NOS LLT
    14.1 10022117 - Injury, poisoning and procedural complications 10020100 Hip fracture PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019986-27 Sponsor Protocol Number: RESPIRO Start Date*: 2010-06-02
    Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO
    Full Title: Breathing disorders in heart failure: high altitude hypoxia as a model to define diagnostic tools, therapeutic strategies and gender related differences.
    Medical condition: Chronic heart failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019280 HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002236-92 Sponsor Protocol Number: 9151 Start Date*: 2011-08-11
    Sponsor Name:Maatschap cardiologie Isala klinieken Zwolle
    Full Title: Dopamine on top of standard treatment for patients with exacerbation of Heart Failure, at home situation
    Medical condition: exacerbation of Heart Failure treated at home
    Disease: Version SOC Term Classification Code Term Level
    13.1 10007541 - Cardiac disorders 10000803 Acute heart failure LLT
    13.1 10007541 - Cardiac disorders 10019284 Heart failure, congestive LLT
    13.1 10007541 - Cardiac disorders 10024106 Left heart failure LLT
    13.1 10007541 - Cardiac disorders 10064082 Heart failure NYHA class IV LLT
    13.1 10007541 - Cardiac disorders 10008908 Chronic heart failure LLT
    13.1 10007541 - Cardiac disorders 10064653 Acute decompensated heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000490-40 Sponsor Protocol Number: S320.2.003 Start Date*: 2007-06-20
    Sponsor Name:Solvay Pharmaceuticals GmbH
    Full Title: Randomised, Double-Blind, Placebo-Controlled, Multi-Center, Sequential Cohort Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects with C...
    Medical condition: Renal Function in Subjects with Congestive Heart Failure and Impaired Renal Function who are on Chronic Furosemide Treatment
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001700-37 Sponsor Protocol Number: CELL-004 Start Date*: 2012-10-03
    Sponsor Name:Celladon Corporation
    Full Title: A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects ...
    Medical condition: Moderate to advanced heart failure (NYHA class II, III or IV) due to systolic dysfunction
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004849 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) BE (Completed) PL (Completed) NL (Completed) DK (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-002168-17 Sponsor Protocol Number: BAY94-8862/16275 Start Date*: 2015-12-09
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to evaluate the efficacy and safety of finerenone compared to eplerenone on morbidity and mortality in...
    Medical condition: Subjects with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004857 10076410 Chronic kidney disease stage 3 LLT
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    20.0 100000004849 10066498 Cardiac failure chronic aggravated LLT
    21.0 100000004857 10076408 Chronic kidney disease stage 1 LLT
    21.0 100000004857 10076409 Chronic kidney disease stage 2 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) LT (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-004186-21 Sponsor Protocol Number: VICTORID_01 Start Date*: 2023-09-14
    Sponsor Name:Dipartimento di Medicina-DIMED, università di Padova
    Full Title: Beneficial effects of vitamin D combined with oral iron supplementation in patients with chronic heart failure and iron deficiency (VICTORID-HF TRIAL)
    Medical condition: Chronic heart failure; iron deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10019284 Heart failure, congestive LLT
    20.0 10007541 - Cardiac disorders 10007558 Cardiac failure chronic PT
    20.1 10007541 - Cardiac disorders 10064081 Heart failure NYHA class III LLT
    20.1 10007541 - Cardiac disorders 10064080 Heart failure NYHA class II LLT
    24.0 100000004861 10060496 Hyposideremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004704-19 Sponsor Protocol Number: 3200 Start Date*: 2016-01-14
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King's College Hospital NHS Foundation Trust
    Full Title: Globifer Forte® Oral Haem and Non-haem Iron Supplementation in Heart Failure: A Randomised, DoubleBlind, Placebo Controlled, Double Dummy, Part Mechanistic.
    Medical condition: Exercise tolerance of Chronic heart failure patients.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-004072-59 Sponsor Protocol Number: 1245-0167 Start Date*: 2018-04-03
    Sponsor Name:Boehringer-Ingelheim España, S.A.
    Full Title: A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In pa...
    Medical condition: Chronic Heart Failure with preserved Ejection Fraction (HFpEF)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) PT (Completed) PL (Completed) SE (Completed) NO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002781-39 Sponsor Protocol Number: CRLX030A2209 Start Date*: 2014-05-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Prospective, Double-Blind, Multicenter Study Evaluating the Safety of Repeat Doses of IV Serelaxin in Subjects with Chronic Heart Failure
    Medical condition: chronic heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) FI (Completed) ES (Completed) SE (Completed) NO (Completed) RO (Completed) NL (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:38:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA